Analysts Set Omnicell, Inc. (NASDAQ:OMCL) PT at $57.86

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $57.8571.

A number of research firms have recently issued reports on OMCL. Piper Sandler reiterated an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Wells Fargo & Company dropped their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Finally, Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OMCL. Versant Capital Management Inc raised its holdings in shares of Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after acquiring an additional 294 shares in the last quarter. Nykredit A S purchased a new position in shares of Omnicell in the second quarter valued at $26,000. Clearstead Advisors LLC increased its position in Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock worth $56,000 after purchasing an additional 1,218 shares during the last quarter. Handelsbanken Fonder AB increased its position in Omnicell by 18.3% in the second quarter. Handelsbanken Fonder AB now owns 12,923 shares of the company’s stock worth $537,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Omnicell in the second quarter worth $105,000. 97.70% of the stock is owned by institutional investors.

Omnicell Stock Performance

Omnicell stock opened at $32.62 on Tuesday. Omnicell has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The stock has a market cap of $1.48 billion, a P/E ratio of 38.83, a price-to-earnings-growth ratio of 0.81 and a beta of 0.97. The firm’s fifty day moving average price is $37.49 and its 200-day moving average price is $38.83.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. During the same period in the previous year, the business earned $0.45 earnings per share. The firm’s quarterly revenue was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, equities research analysts expect that Omnicell will post 1.41 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.